# A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Study · id `cardio:ct-nct06717698` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06717698](<https://clinicaltrials.gov/study/NCT06717698>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06717698

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 465 participants.

## Technical summary

Registry record NCT06717698. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-02 (actual); primary completion 2026-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 465 participants (planned count; ClinicalTrials.gov record NCT06717698, source copy `cardio:ctgov-nct06717698-2026-03-11`, retrieved 2026-10-26)
- Started: 2024-12-02 (actual) (ClinicalTrials.gov record NCT06717698, source copy `cardio:ctgov-nct06717698-2026-03-11`, retrieved 2026-10-26)
- Primary completion: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT06717698, source copy `cardio:ctgov-nct06717698-2026-03-11`, retrieved 2026-10-26)
- Completion: 2026-09-17 (anticipated) (ClinicalTrials.gov record NCT06717698, source copy `cardio:ctgov-nct06717698-2026-03-11`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Czechia; India; Italy; Japan; Malaysia; Poland; South Korea; Spain; Türkiye (ClinicalTrials.gov record NCT06717698, source copy `cardio:ctgov-nct06717698-2026-03-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06717698-2026-03-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- Condition: Chronic Kidney Disease
- Intervention (Drug): NNC0519-0130
- Intervention (Drug): Placebo
- Intervention (Drug): Semaglutide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 456fda65ced4ca4a4784f9c2c17f4ce03bdb5c7d05b5dcc6429905a44b795e35
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
